- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT04970914
Anlotinib Plus Penpulimab (AK105) for Chemo-refractory Metastatic Colorectal Cancer:ALTER-C003 (ALTER-C003)
6. marts 2022 opdateret af: YueJuan Cheng, Peking Union Medical College Hospital
Anlotinib Hydrochloride In Combination With Penpulimab (AK105) in Patients With Chemo-refractory Metastatic Colorectal Cancer, Open, Single Arm,Exploratory Clinical Trial(ALTER-C003)
A single-arm, open-label clinical trial, focus on the safety and efficacy of anlotinib hydrochloride in combination with Penpulimab (AK105) in patients with Chemo-refractory Metastatic Colorectal Cancer (mCRC)
Studieoversigt
Status
Rekruttering
Betingelser
Intervention / Behandling
Undersøgelsestype
Interventionel
Tilmelding (Forventet)
32
Fase
- Fase 2
Kontakter og lokationer
Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.
Studiekontakt
- Navn: Jianfeng Zhou
- Telefonnummer: 011-86-10-69156114
- E-mail: ZhouJF@pumch.cn
Studiesteder
-
-
-
Beijing, Kina
- Rekruttering
- Peking Union Medical College Hospital
-
Kontakt:
- jianfeng Zhou
- E-mail: ZhouJF@pumch.cn
-
Shenyang, Kina
- Ikke rekrutterer endnu
- The First Hospital of China Medical University
-
Kontakt:
- Xiujuan Qu
-
Shenyang, Kina
- Ikke rekrutterer endnu
- The People's Hospital of Liaoning Province
-
Kontakt:
- Du Zhenguang
-
-
Beijing
-
Beijing, Beijing, Kina
- Rekruttering
- Beijing Tiantan Hospital, Capital Medical University
-
Kontakt:
- Xiaoyuan Li
-
Ledende efterforsker:
- Xiaoyuan Li
-
Beijing, Beijing, Kina
- Ikke rekrutterer endnu
- China-Japan Friendship Hospital
-
Ledende efterforsker:
- Yuan Li
-
Kontakt:
- Yuan Li
-
-
Hebei
-
Langfang, Hebei, Kina
- Ikke rekrutterer endnu
- Hebei Petro China Central Hospital
-
Kontakt:
- Qian Guo
-
Ledende efterforsker:
- Qian Guo
-
Shijiazhuang, Hebei, Kina
- Ikke rekrutterer endnu
- The Fourth Hospital of Hebei Medical University (Hebei Cancer Hospital)
-
Ledende efterforsker:
- Ruixing Zhang
-
Kontakt:
- Ruixing Zhang
- Telefonnummer: 0086-311-86095757
-
-
Tianjin
-
Tianjin, Tianjin, Kina
- Rekruttering
- General Hospital of Tianjin Medical University
-
-
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
18 år og ældre (Voksen, Ældre voksen)
Tager imod sunde frivillige
Ingen
Køn, der er berettiget til at studere
Alle
Beskrivelse
Inclusion Criteria:
- Patients participate in the study voluntarily and sign informed consent with good compliance.
- Be 18 years of age or older on day of signing informed consent.
- Histological or cytological confirmation of Metastatic Colorectal Cancer(T1-4N0-2M1).
- At least one measurable lesion, with diameter ≥ 10mm measured by spiral MRI/CT scan per RECIST1.1.
- Participants must have received and progressed through or become intolerant to fluoropyrimidine, irinotecan, oxaliplatin, Exceptions may apply.
- Eastern Cooperative Oncology Group Performance Status 0 or 1.
- Life expectancy of at least 3 months.
- Main organs function is normal. (normal main organs function as defined below: Hemoglobin (Hb) ≥ 90 g/L, Neutrophils (ANC) ≥ 1.5×109/L, leucocyte (WBC) ≥ 3.0×109/L,Platelet count (PLT) ≥ 75×109/L,Total bilirubin (TBIL) ≤ 1.5 × normal upper limit (ULN), Aspartate aminotransferase (AST) and Alanine aminotransferase (ALT) ≤ 2.5 ×ULN, If liver metastasis is present,ALT and AST<5ULN ;Serum creatinine (Cr) ≤ 1.5× ULN or Creatinine Clearance rate(CCr) ≥60ml/min,Doppler ultrasound evaluation: left ventricular ejection fraction (LVEF) > 50%)
- The woman patients of childbearing age who must agree to take contraceptive methods (e.g. intrauterine device, contraceptive pill or condom) during the research and within another 3 months after it; who are not in the lactation period and examined as negative in blood serum test or urine pregnancy test within 7 days before the research; The man patients who must agree to take contraceptive methods during the research and within another 8 weeks after it.
Exclusion Criteria:
- Histological or cytological confirmation of mucinous adenocarcinoma or ovarian transcoelomic metastasis
- Patients who had previously received treatment with Anlotinib or anti-programmed cell death protein 1 (PD-1), programmed cell death protein 1 ligand 1 (PD-L1), or cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitors other immunotherapy against .
- Patients who had previously received treatment within 2 weeks or Participated in other anti-tumor clinical trials within 4 weeks.
- Patients with a large amount of pleural effusion or ascites requiring drainage.
- Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis.
- Has a known additional malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or in situ cervical cancer that has undergone potentially curative therapy.
- Patients who underwent major surgery within 4 weeks.
- Regardless of the severity, patients with any physical signs or history of bleeding, patients with bleeding or bleeding events greater than or equal to CTCAE 3 within four weeks prior to the first administration, or patients with unhealed wounds, fractures, ulcers.
- Patients with a risk of gastrointestinal bleeding may not be enrolled.
- Patients with arterial or venous thromboembolic events occurred within 6 months, such as cerebrovascular accident (including transient ischemic attack), deep vein thrombosis and pulmonary embolism.
- Patients with any severe and/or unable to control diseases,including: Patients with unsatisfactory blood pressure control using antihypertensive drugs (systolic blood pressure ≥150 mmHg or diastolic blood pressure ≥100) mmHg); Patients with Grade 2 or higher myocardial ischemia, myocardial infarction or malignant arrhythmias(including male QTc≥450ms; female QTc≥470ms) and patients with Grade 2 or higher congestive heart failure (NYHA Classification); Patients with active or unable to control serious infections, which is over level 2 in CTC AE (4.0); Patients with poorly controlled diabetes (fasting blood glucose(FBG)>10mmol/L); Patients with kidney failure who require hemodialysis or peritoneal dialysis; Patients with interstitial lung disease with symptoms or signs of activity;Patients with a history of immunodeficiency, including a positive HIV test or other acquired, congenital immunodeficiency disease, or a history of organ transplantation; Urine routine indicates that urine protein ≥ ++, and confirmed 24-hour urine protein quantitation > 1.0 g; Patients with any of the following coagulation functions are abnormal, including: Prothrombin time (PT)>ULN+4s, Activated partial thromboplastin time (APTT) >1.5ULN s, international normalized ratio (INR)>1.5; Patients with a seizure disorder who require pharmacotherapy.
- Patients who have got non remissive toxic reactions derived from any treatment, which is over level 1 in CTC AE (4.0).
- Has a diagnosis of immunodeficiency or is receiving chronic steroid therapy of prednisone ≥ 10 mg daily or any equivalent dose of corticosteroids.
- Has received a live vaccine or attenuated vaccine within 30 days prior to trial registration.
- Symptoms that affect oral medication and cannot be controlled through proper treatment (such as inability to swallow, chronic diarrhoea and intestinal obstruction, etc.).
- Female patients who are pregnant or breastfeeding.
- Patients with drug abuse history and unable to get rid of or patients with mental disorders.
- Patients who had serious adverse effect to Anlotinib or Penpulimab or any of its excipients
- Known hypersensitivity to other Monoclonal Antibody or any of its excipients.
- Patients with concomitant diseases which could seriously endanger their own safety or could affect completion of the study according to investigators' judgment.
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Eksperimentel: Anlotinib+Penpulimab
|
Penpulimab 200 mg administreret intravenøst hver 3. uge.
Andre navne:
12 mg, kontinuerlig oral 2 ugers stop i 1 uge, 21 dage for en behandlingscyklus.
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Progression-free survival (PFS)
Tidsramme: up to 24 months
|
Progression-free Survival (PFS) (median) was determined using the number of months measured from the initial date of treatment to the date of documented progression, or the date of death (in the absence of progression) of participants.
Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.
|
up to 24 months
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Disease Control Rate (DCR)
Tidsramme: op til 24 måneder
|
Sygdomskontrolfrekvens er defineret som procentdelen af forsøgspersoner, hvis bedste respons var CR, PR eller stabil sygdom (SD) ifølge RECIST v1.1.
|
op til 24 måneder
|
Objective Response Rate (ORR)
Tidsramme: up to 24 months
|
Objective response rate is defined as the percentage of subjects whose best response was complete response (CR) or partial response (PR) according to the RECIST v1.1
|
up to 24 months
|
Duration of Response (DOR)
Tidsramme: up to 24 months
|
Duration of Response is defined as the percentage of subjects whose best response was CR, PR or stable disease (SD) according to the RECIST v1.1 or death due to any cause, whichever occurs first.
|
up to 24 months
|
Number of participants with treatment-related adverse events as assessed by CTCAE v5.0
Tidsramme: Until 30 day safety follow-up visit
|
Adverse events assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events (version 5.0).
|
Until 30 day safety follow-up visit
|
Overall Survival (OS)
Tidsramme: Up to 24 months
|
Overall Survival (OS) (median) is determined using the number of months measured from the initial date of treatment to the recorded date of death of participants.
|
Up to 24 months
|
Andre resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Number of TB cells count and interleukin-6/8/10
Tidsramme: through study completion, an average of 2 year
|
Objectives to analyse the subsets of TB cells and interleukin-6/8/10 associated treatment.
|
through study completion, an average of 2 year
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Efterforskere
- Ledende efterforsker: Jianfeng Zhou, Peking Union Medical College Hospital
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart (Faktiske)
5. november 2021
Primær færdiggørelse (Forventet)
23. august 2022
Studieafslutning (Forventet)
23. august 2023
Datoer for studieregistrering
Først indsendt
5. juli 2021
Først indsendt, der opfyldte QC-kriterier
13. juli 2021
Først opslået (Faktiske)
21. juli 2021
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
8. marts 2022
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
6. marts 2022
Sidst verificeret
1. marts 2022
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- HS-2986B
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
INGEN
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Ingen
Studerer et amerikansk FDA-reguleret enhedsprodukt
Ingen
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Kolorektal cancer
-
University of ArkansasAktiv, ikke rekrutterendeColorectal cancer og inflammatorisk tarmsygdomForenede Stater
-
University Health Network, TorontoAstraZenecaAktiv, ikke rekrutterendeAdenocarcinom i bugspytkirtlen | Leiomyosarkom | Mismatch Reparation Proficient Colorectal CancerCanada
-
Tianjin Medical University Cancer Institute and...RekrutteringMSI-H Advanced Colorectal CancerKina
-
Bristol-Myers SquibbAktiv, ikke rekrutterendeMikrosatellit stabil kolorektal cancer | Mismatch Reparation Proficient Colorectal Cancer | Mikrosatellit ustabil kolorektal cancer | Mismatch Reparation Manglende tyktarmskræftForenede Stater, Australien, Belgien, Canada, Irland, Italien, Spanien, Frankrig
-
Syndax PharmaceuticalsMerck Sharp & Dohme LLCAfsluttetMelanom | Ikke-småcellet lungekræft | Mismatch Reparation-Proficient Colorectal CancerForenede Stater
Kliniske forsøg med Penpulimab
-
Hunan Cancer HospitalFuzhou Pulmonary Hospital of Fujian; Chia Tai Tianqing Pharmaceutical Group...RekrutteringSmåcellet lungekræftKina
-
Hunan Cancer HospitalHenan Cancer Hospital; Chia Tai Tianqing Pharmaceutical Group Co., Ltd.RekrutteringIkke småcellet lungekræftKina
-
Sun Yat-sen UniversityIkke rekrutterer endnu
-
Peking Union Medical College HospitalRekrutteringFæokromocytom, metastatisk | Paragangliom, ondartet | Malignt fæokromocytomKina
-
Peking Union Medical College HospitalIkke rekrutterer endnuUndersøgelse af anlotinib hos patienter med radioiod-refraktær differentieret skjoldbruskkirtelkræftLokalt avanceret eller metastatisk radiojod-refraktært differentieret skjoldbruskkirtelcarcinomKina
-
Zhongda HospitalRekruttering
-
The First Affiliated Hospital of Zhengzhou UniversityIkke rekrutterer endnuLivmoderhalskræft
-
Tang-Du HospitalIkke rekrutterer endnu
-
The Central Hospital of Lishui CityIkke rekrutterer endnu
-
West China HospitalIkke rekrutterer endnu